Author Correction: Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease

Sci Rep. 2018 May 24;8(1):8266. doi: 10.1038/s41598-018-23083-1.

¹ IRCCS Neuromed, Pozzilli, Italy.
² Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, Genova, Italy.
³ Departments of Pediatrics, Neurology and Biochemistry, Vanderbilt University (VU) and VU Medical Center Pediatric Neurology Research Lab, Nashville, TN, USA.
⁴ John van Geest Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK.
⁵ Institute of Biosciences and Bioresources (IBBR), National Research Council (CNR), Naples, Italy.
⁶ Department of of Cosmetic Science, Seowon University, Cheongju, Korea.
⁷ NeoPharm USA Inc. Engelwood Cliffs, New Jersey, USA.
⁸ Institute of Genetics and Biophysics "A. Buzzati-Traverso", Naples, Italy.
⁹ IRCCS Neuromed, Pozzilli, Italy. vittorio.maglione@neuromed.it.

Abstract

A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.